California Voters Divided in Support of Ballot Measure That Would Fund Stem Cell Research
By Kaiser Daily Women's Health Policy Report,
Kaiser Daily Women's Health Policy Report
| 08. 16. 2004
California voters are "almost evenly divided" on a ballot measure that would provide the state with nearly $3 billion in funding for human embryonic stem cell research, according to a Field Poll survey released on Sunday, Reuters reports (Reuters, 8/15). Under the measure, which will appear on the Nov. 2 ballot as Proposition 71, the California Stem Cell Research and Cures Initiative, organized by Californians for Stem Cell Research and Cures, would provide $295 million in state funds annually for 10 years to California schools, institutes and companies that conduct embryonic stem cell research. The initiative would provide grants and loans to organizations that use stem cells derived from human embryos that are less than two weeks old. The measure also would create a 29-member panel -- appointed by the governor, University of California chancellors and other officials -- that would determine allocation of the grants, which would be provided only to California organizations. If the ballot measure is successful, California would become the first state to publicly fund embryonic stem cell research, which some scientists believe...
Related Articles
By Tomoko Otake, The Japan Times | 04.09.2024
A decade ago, researcher Haruko Obokata caused a sensation when she published two papers in the journal Nature, in which she claimed that she had discovered a way to create stem cells easily using the so-called STAP method.
With STAP...
By Ian Sample, The Guardian | 03.08.2024
Scientists are a step closer to making IVF eggs from patients’ skin cells after adapting the procedure that created Dolly the sheep, the first cloned mammal, more than two decades ago.
The work raises the prospect of older women being...
By Ramon Antonio Vargas, The Guardian | 02.28.2024
Doctors say a man in California who contracted blood cancer while living with HIV is in remission from both potentially fatal illnesses thanks to a treatment they are hailing as remarkable and encouraging.
Paul Edmonds is only the fifth-known person...
By Victoria Gray, Uduak Thomas, and Kevin Davies, The CRISPR Journal | 02.14.2024
In July 2019, medical staff in Nashville dosed the first U.S. patient in the exa-cel therapy trial, sponsored by Vertex Pharmaceuticals and CRISPR Therapeutics. That first patient was Victoria Gray, a mother of four from Forest, Mississippi, a sickle cell...